<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688868</url>
  </required_header>
  <id_info>
    <org_study_id>Firehawk_SS</org_study_id>
    <nct_id>NCT02688868</nct_id>
  </id_info>
  <brief_title>Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )</brief_title>
  <official_title>The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evalute the clinical safety and effectiveness of released
      specification (2.25mm) of FirehawkTM Sirolimus target-eluting coronary stent system.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent Late Loss</measure>
    <time_frame>9 month after stent implantation</time_frame>
    <description>the difference between the minimal lumen diameter immediately after stent implantation and the minimal lumen diameter by angiography review 9 months after the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>12 months</time_frame>
    <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>2 years</time_frame>
    <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>3 years</time_frame>
    <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>4 years</time_frame>
    <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MACE</measure>
    <time_frame>12 months</time_frame>
    <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MACE</measure>
    <time_frame>2 years</time_frame>
    <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MACE</measure>
    <time_frame>3 years</time_frame>
    <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MACE</measure>
    <time_frame>4 years</time_frame>
    <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>new specifications (Diameter 2.25mm)of Firehawk stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FirehawkTM 2.25mm</intervention_name>
    <description>Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
    <arm_group_label>new specifications (Diameter 2.25mm)of Firehawk stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-80 years of age, males or non-pregnant women;

          2. Evidence of silent ischemia, stability or in patients with old myocardial infarction
             or unstable angina;

          3. Primary target lesion, in situ coronary artery disease;

          4. Target lesion length ≤ 60mm, target lesion diameter 2.25mm (Visual method);

          5. The target lesion diameter stenosis ≥ 70% (Visual method);

          6. Each target lesion implantation the same stent (Firehawk stent);

          7. With indications for coronary artery bypass surgery;

          8. To understand the purpose of testing, voluntary and informed consent, patients agreed
             to achieve invasive imaging and clinical follow-up.

        Exclusion Criteria:

          1. Within 72h of any acute myocardial infarction;

          2. Unprotected left main coronary artery disease, triple vessel lesions which need
             treated all; bifurcation lesions and vascular lesions of the bridge;

          3. Severe calcified lesions that cannot be successfully expanded and distorting lesions
             not suitable for stent delivery;

          4. Artery and/or vein bypass graft lesions;

          5. Intracoronary implantation of any branding stents within 1 year;

          6. Severe congestive heart failure (NYHA class III and above), or left ventricular
             ejection fraction &lt;35% (ultrasound or left ventricular angiography);

          7. Preoperative renal function serum creatinine &gt;2.0mg/DL;

          8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage
             and half year history of ischemic stroke, antiplatelet agents and would not allow an
             anticoagulant therapy contraindications patients undergoing antithrombotic therapy;

          9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin
             allergies;

         10. The patient's life expectancy is less than 12 months;

         11. Top participated in other drug or medical device and does not meet the primary study
             endpoint in clinical trials time frame;

         12. Researchers determine patient compliance is poor, unable to complete the study in
             accordance with the requirements;

         13. Heart transplantation patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Wai Hospital &amp; National Center for Cardiovascular Diseases in China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fu Wai Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <results_first_submitted>January 28, 2020</results_first_submitted>
  <results_first_submitted_qc>February 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2020</results_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
          <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
          <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.22" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>In-stent Late Loss</title>
        <description>the difference between the minimal lumen diameter immediately after stent implantation and the minimal lumen diameter by angiography review 9 months after the procedure.</description>
        <time_frame>9 month after stent implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent Late Loss</title>
          <description>the difference between the minimal lumen diameter immediately after stent implantation and the minimal lumen diameter by angiography review 9 months after the procedure.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
        <time_frame>3 years</time_frame>
        <population>One missed participant in 3 years follow up</population>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
          <population>One missed participant in 3 years follow up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
        <time_frame>4 years</time_frame>
        <population>Two missed participant in 4 years follow up</population>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization</description>
          <population>Two missed participant in 4 years follow up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MACE</title>
        <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MACE</title>
          <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MACE</title>
        <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MACE</title>
          <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MACE</title>
        <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
        <time_frame>3 years</time_frame>
        <population>One missed participant in 3 years follow up</population>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MACE</title>
          <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
          <population>One missed participant in 3 years follow up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MACE</title>
        <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
        <time_frame>4 years</time_frame>
        <population>One missed participant in 3 years follow up</population>
        <group_list>
          <group group_id="O1">
            <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
            <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MACE</title>
          <description>a composite endpoint of all cause death, any myocardial infarction and any revascularization</description>
          <population>One missed participant in 3 years follow up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>New Specifications (Diameter 2.25mm)of Firehawk Stent</title>
          <description>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
FirehawkTM 2.25mm: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>target lesion revascularization</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>in-stent restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>angina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>non target lesion revascularization</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>rehospitalization</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Death of cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>renal artery implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>elevated myocardial enzyme</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>No-reflow phenomenon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>intermediate lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>perioperation slow heart beat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Heart dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myocardial injury</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>rapid heart beat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Chest distress</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deaf</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastroesophageal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Repeat chest &amp; back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>abnormal liver function</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>unsatifactory blood glucose control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cervical spondylopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>disc herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleeping disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>soft tissue disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>lumbago</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>perioperation hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Varicosity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>HT Zhang</name_or_title>
      <organization>Shanghai Microport Medicine</organization>
      <phone>+862138954600 ext 8552</phone>
      <email>zhanght@microport.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

